title: [Soluble CD40 ligand in systemic lupus erythematosus: link with atherosclerotic vascular affection].
abstract: OBJECTIVE
  To evaluate clinical implications of pCD40L as a marker of atherosclerotic vascular affection in systemic lupus erythematosus (SLE).
  
  
  METHODS
  The examination of 132 females (mean age 35 years, SLE duration 96 months) assessed classic factors of atherosclerosis risk (AR), total coronary risk (TCR), detected subclinical atherosclerosis with ultrasonic scanning of the carotid arteries. Serum level of pCD40L was measured with enzyme immunoassay (EL4).
  
  
  RESULTS
  Concentration of pCD40L in SLE patients was higher than in the control group (7.1 +/- 4.9 and 5.8 +/- 3.1 ng/ml, respectively) but the difference was insignificant (p > 0.05). Upper limit of normal value (M + 2SD) for pCD40L was 12 ng/ml. Elevation of pCD40L level was seen in 21% of SLE patients. Clinical manifestations of atherosclerosis risk were seen in 13% SLE patients, subclinical in 19 and 17% (increased intima-media thickness and atherosclerotic plaques, respectively). No correlations were found between pCD40L level and atherosclerotic symptoms. The pCD40L level was higher in SLE patients with the plaques than in those without them (p = 0.005). A positive correlation exists between a pCD40L concentration and maximal intima-media thickness (r = 0.2; p = 0.02), total cholersterol (r = 0.3; p = 0.002), LDLP cholesterol (r = 0.3; p = 0.004), LDLP cholesterol (r = 0.2; p = 0.04) and age of the patients (r = 0.2; p = 0.03). In patients with TCR > 20% a pCD40L was significantly higher than in patients with TCR < 20% (p = 0.01).
  
  
  CONCLUSIONS
  Elevated pCD40L level is a marker of atherosclerotic affection of the vessels, has an important clinical role for predicting risk of cardiovascular diseases in SLE and elicidation of the role of activation of cell immunity in development of atherosclerosis in this disease.
authors.forename: T V
authors.initials: TV
authors.lastname: Popkova
authors.forename: T A
authors.initials: TA
authors.lastname: Panafidina
authors.forename: E N
authors.initials: EN
authors.lastname: Aleksandrova
authors.forename: D S
authors.initials: DS
authors.lastname: Novikova
authors.forename: A A
authors.initials: AA
authors.lastname: Novikov
authors.forename: Z S
authors.initials: ZS
authors.lastname: Alekberova
authors.forename: E S
authors.initials: ES
authors.lastname: Mach
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D000328:Adult; D050197:Atherosclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D015415:Biomarkers / Q000097:blood; D023201:CD40 Ligand / Q000097:blood*; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications; D011379:Prognosis; D012307:Risk Factors; D014463:Ultrasonography
chemical_list: D015415:Biomarkers; D023201:CD40 Ligand